Form 4: Ligand Pharma CEO Gifts Shares to Charitable Entity

Ligand Pharmaceuticals CEO Todd C. Davis reported a gift of 130 common shares to a charitable entity.

Summary

• Todd C. Davis, Chief Executive Officer and Director of Ligand Pharmaceuticals Inc. (LGND), reported a transaction.
• The transaction involved a gift of 130 shares of Ligand Pharmaceuticals Common Stock.
• The shares were gifted to a charitable entity, as indicated by the transaction code 'G' and explanation.
• The transaction occurred on December 4, 2025.
• Following this transaction, Todd C. Davis beneficially owns 161,337 shares of Common Stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine insider transaction involving a charitable gift, which has no direct positive or negative financial implications for the company's operational performance or future prospects. It's a personal philanthropic act by the CEO.

Positives

• The gift to a charitable entity demonstrates philanthropic activity by the CEO.

Negatives

• A minor reduction in the direct beneficial ownership of common stock by the CEO, though the amount is negligible.

Management Comments

• The transaction represents a bona fide gift of shares to a charitable entity.

Stakeholder Impact

• Minimal impact on shareholders due to the small number of shares involved relative to the company's total outstanding shares.
• Potentially positive perception for the company due to the CEO's charitable giving.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Todd C. Davis, Form 4, Insider Transaction, Share Gift, Charitable Donation, CEO Stock Ownership